Kornimate/medical-research-clean huggingface dataset:
development and validation of a new digital dermatoscope in the united states

Conditions: Skin Cancer

Summary: a completely new type of digital dermatoscope has been developed in order to take a significant step forward in technology for skin cancer imaging. by means of this study a better insight can be gained of the current performance and workflow in clinical dermatoscopy. this knowledge will be used to further improve the developed technology.


Eligibility criteria:
inclusion criteria: * participant is willing and able to give informed consent for participation in the study. * male or female, aged 18 years or above. * male or female, aged less than 18 years, with informed consent of their legally authorized representative. * patient presenting with any visible skin lesion for dermatologist review on a body site amenable to optimal photographic imaging. * able and willing to comply with all study requirements. * patient with a skin lesion that is clinically diagnosed by a dermatologist as benign, malignant or a suspicious skin lesion requiring excisional biopsy for histological diagnosis. exclusion criteria: * patients aged under 18 years old where the legally authorized representative is unable or unwilling to provide their informed consent. * patients unable to provide informed consent. * skin lesions in an anatomical site which is not suitable for photography including hair-obscured site, subungual lesion or inaccessible mucosal site. * lesion is at a site where previous surgery was undertaken.
comparison the effectiveness of mirror therapy vs music therapy for training in post stroke hemiplegic patients

Conditions: Hemiplegia

Summary: a randomized clinical trial was performed on hemiplegic post-stroke patients with a sample size of 50 (25 in each group).

it was a single-blinded study. mirror therapy was given to group a and music therapy was given to group b. our findings support the alternate hypothesis. this indicates the small effect size for bbs in group a and the moderate effect size for the gait assessment scale in favor of group a.

Eligibility criteria:
inclusion criteria: * ischemic and hemorrhagic post stroke hemiplegic patients * patients of age 40-60 years * no visual perception dysfunction exclusion criteria: * patients with fracture of upper or lower limb * patient with comorbidities * patients with hearing issues * patients with cognitive disabilities * patient with other neurological disease
a study to document and to further describe long-term safety and effectiveness of palovarotene in participants with fibrodysplasia ossificans progressiva (fop)

Conditions: Fibrodysplasia Ossificans Progressiva

Summary: the participants in this registry study will have fibrodysplasia ossificans progressiva (fop). fop is an ultra-rare, severely disabling disease characterized by new bone formation in areas of the body where bone is not normally present (heterotopic ossification (ho)). ho is often preceded by painful, recurrent episodes of soft tissue swelling (flare-ups). this registry study will take place in countries where the treatment, known as palovarotene has been approved for use. participants will already be receiving palovarotene as prescribed by their treating physician according to locally approved product information. the main aim of this study will be to collect and assess real-world safety data on children and adult participants with fop treated with palovarotene. this study will also describe the effectiveness of this treatment, including the effect on everyday activities and physical performance


Eligibility criteria:
inclusion criteria : * adult or child with fop who have been prescribed palovarotene (prior to and independently of the decision to enroll the patient in this registry study and as per local label) by their treating physician according to the locally approved product information; * signed informed consent as per local regulations must be obtained and maintained. consent/assent from the participant should be obtained as appropriate before any registry study data collection are conducted. if applicable, parents or legally authorized representatives must give signed informed consent. exclusion criteria : * currently participating in a palovarotene clinical trial; * currently participating in any interventional clinical trial for fop; * have any contraindication to palovarotene as per the locally approved label (except for pregnant women who have previously received and discontinued palovarotene at any time during the pregnancy and who will be included for safety follow-up).
guidewire use in nasotracheal intubation

Conditions: Epistaxis Nosebleed; Pharyngeal Bleeding

Summary: during nasotracheal intubation, nasopharyngeal trauma and associated bleeding may occur. the investigators think that some of this bleeding is due to trauma to the posterior wall of the nasopharynx. the investigators designed this study, thinking that if nasopharyngeal posterior wall trauma can be prevented, some of these bleedings can be prevented.

nasotracheal intubation (nti) is a frequently used airway management method in pedodontic dental treatments performed under general anesthesia. however, nasopharyngeal trauma and associated bleeding are common during conventional nti. in this study, the investigators aimed to examine the effect of angling the end of the endotracheal tube (ett) by placing a guide wire inside the ett on nasopharyngeal bleeding. the patients included in the study were randomized into two groups. in the control group (group c), nti will be done conventionally. in the study group (group s), a guide wire will be inserted into the ett before intubation and angled 100-120 degrees to the distal end (in the shape of a hockey stick). the angulation will not be sharp but slightly curved and the apex of the angulation will be 2.5-3 cm proximal from the distal end. the ett will be positioned perpendicular to the face and inserted into the nostril. after the angled part of the ett passes through the nostrils, it will be directed to caudally according to the angle given to the tip of the ett. meanwhile, the ett will be moved as a whole to prevent the ett tip from contacting the posterior wall of the nasopharynx. when the ett tip reaches the oropharynx, the guidewire will be removed and the rest of the intubation will be completed as in the conventional method.

Eligibility criteria:
inclusion criteria: * 2-12 years old * american society of anesthesiologists i-iii * patients with elective dental surgery * patients whose parents have accepted informed consent forms * patients without previous nasopharyngeal anomalies * patients without previous nasopharyngeal surgeries * patients without upper airway infections exclusion criteria: * under 2 or over 12 years old * emergency surgeries * patients whose parents have not accepted informed consent forms * patients with previous nasopharyngeal anomalies * patients with previous nasopharyngeal surgeries * patients with upper airway infections

Keywords: airway management intubation complication nasotracheal intubation nasal bleeding
lung ultrasound for the postoperative diagnosis of pneumothorax in children

Conditions: Pectus Excavatum

Summary: this study will be conducted to determine the advantages and limitations of sonography compared with chest radiography, in the detection of post procedure iatrogenic pneumothorax in patients underwent to pectus excavatum (pe) with nuss repair.

the nuss procedure is a minimally invasive technique for the repair of pectus excavatum (mirpe). residual pneumothorax (pnx) is reported in more than 50% after nuss procedure. it is a consequence of the introduction of the scope and bar in the pleural space and is considered a minor complication due to the minimal clinical consequences. it is routine practice to confirm the diagnosis of pnx with a conventional chest x-ray either in the operating room at the end of thoracic surgery or in the recovery room unit immediately after surgery.however, anterior pneumothorax can occur and chest-x ray could not be able to detected the pnx. nowadays lung ultrasound (lus) allows a bedside non-invasive evaluation of the patient(with a sensitivity and specificity of 92 and 99% respectively) without exposure to ionized radiation, can be performed more quickly than chest radiography and therefore can be repeated several times without additional risks. the use of lus in pediatric age groups is more recent, but is becoming widely utilized both in neonatal and pediatric respiratory diseases. bedside sonography for diagnosis of pnx has been well described in emergency and trauma medicine literature and it is resulted to be more sensitive and specific than portable anteroposterior chest radiography. although there are few studies describing the use of ultrasound for the detection of surgical pneumothorax, none of them studied its use after nuss procedure.

Eligibility criteria:
inclusion criteria: * patients following nuss procedure for pe repair at giannina gaslini institute exclusion criteria: * absence of informed consent from parents * poor quality of the pre-operatory acoustic window
stroke prophylaxis of af-patients: real-life effectiveness and safety of novel anticoagulants compared to vka

Conditions: Atrial Fibrillation; Stroke Prophylaxis

Summary: the central questions of the study can be summarized as follows: what stroke / death rates are the result of the use of the following treatment strategies: no anticoagulation with vitamin-k-antagonists (vkas) or novel oral anticoagulants (noacs), anticoagulation with vkas and anticoagulation with noacs (all). what other thromboembolic complication rates resulting from the use of these treatment strategies? what heavy bleeding rates resulting from the defined management strategies? the analysis is based on a data set of patients with atrial fibrillation (af)(01/01/2010 - 30/06/2014). 2010 is used as the reference period and 01/01/2011-30/06/2013 as the inclusion period. the minimum observation time per patient is 12 months. used is a data base of the aok plus as well as the aok baden-württemberg and aok bayern. the aim of the study is to compare clinical outcomes between the different treatment strategies (frequency of events and time to first event). the influence of alternative treatment strategies is measured on the basis of three different methodological approaches: unadjusted comparison of event council and time to first event between the defined patient groups; matched-pair comparison (propensity score matching) between the different groups of patients (treatment strategies) and multivariate analysis using time to event (cox proportional hazards model) as the dependent variable.


Eligibility criteria:
inclusion criteria: * one inpatient or two outpatient confirmed diagnosis of atrial fibrillation in two different quarters * continuously insured by the aok plus, aok bayern or aok baden-württemberg exclusion criteria: * age \< 18 years * maximum possible observational period \< 12 months (exception: death)
real-time myocardial perfusion echocardiography in the icu

Conditions: Myocardial Perfusion Imaging

Summary: this study is being done to find out if and how much the use of rtmpe improves a provider's confidence in the diagnosis they assign. this is important because the use of rtmpe may decrease the need for any additional invasive testing.

the finding of elevated troponins and regional wall motion abnormalities on echocardiography in the absence of other signs of acute coronary syndrome among the intensive care population creates a diagnostic challenge for evaluation. sometimes these ill patients undergo invasive coronary angiography to rule out acute thrombosis. real-time myocardial perfusion echocardiography (rtmpe) is a safe and accurate imaging modality to assess perfusion and can be performed in the resting state at the bedside in the intensive care unit (icu) to help stratify the likelihood intracoronary thrombosis as the etiology for abnormal troponins and/or echocardiography. the primary aim of this study is to evaluate the impact of rtmpe on providers' diagnostic confidence using a 5-point likert scale for patients that receive a standard transthoracic echocardiogram (tte) compared to patients that receive rtmpe. the rtmpe to assess perfusion will be added to the standard transthoracic echocardiogram in approximately 24 patients undergoing evaluation of myocardial ischemia in medical or surgical icus. the caring provider will complete a web-based survey regarding their confidence in the diagnosis prior to and after the study in both groups. the images will be interpreted by an experienced cardiologist and results will be made available in the medical record. the difference in diagnostic confidence scores will be analyzed using the wilcoxon signed-rank test. the secondary aims are to assess the management and outcomes in both groups.

Eligibility criteria:
inclusion criteria: 1. adults age ≥ 18 years 2. located in a designated icu 3. tte ordered by the primary care team 4. significant delta in troponin trend 5. concern for myocardial ischemia 6. women of child-bearing potential must have a clinical negative pregnancy test result 7. experienced sonographer available to complete rtmpe portion of the exam 8. provider willing to complete the study survey exclusion criteria: 1. adults \< 18 years 2. contraindication to echo contrast administration 3. location other than an icu 4. no significant delta in troponin trend

Keywords: definity contrast
metabolic dynamics during physical activity

Conditions: Healthy Men and Women

Summary: the aim of this study is to systematically analyse the metabolome in capillary blood of healthy men and women at rest and during defined standardized physical activity under normobaric normoxia or hypoxia with a specific focus on metabolites and metabolic pattern related to energy metabolism. the metabolome analyses in capillary blood could give us also or more detailed insight into erythrocyte metabolic physiology because it is known for a longer time that the primary metabolism of the erythrocyte reflects its oxygen saturation via the glycolytic metabolites / intermediates pattern.


Eligibility criteria:
inclusion criteria: * healthy volunteers * written informed consent exclusion criteria: * known cardio-vascular, lung, metabolic, endocrine, hematologic, kidney or neurologic diseases * pregnancy, lactating period * unability to understand study content and aims and to give written informed consent

Keywords: metabolism metabolome physical activity hypoxia
oral glucosestimulation after gastric bypass surgery

Conditions: Obesity

Summary: the objective of this study is to examine gastric emptying and satiety hormones after oral glucose stimulation in 2 different concentrations in morbidly obese patients after roux-en-y-gastric-bypass.

after gastric bypass many patients suffer from early and/or late dumping syndrome as a reaction to carbohydrate rich meals. gastric emptying after bypass is accelerated and nutrition enters the intestine faster, which leads to osmotically driven fluid shifts from the blood to the lumen. late dumping occurs 1-3 h after eating, and is caused by hyperinsulinemia and is therefore characterized by symptoms of hypoglycemia like weakness, sweating, and dizziness. many people have both types. in most studies examining satiety hormones after oral glucose stimulation in non-operated patients, glucose loads of 50-75g are used. for a measurable glp-1 rise a threshold of 2 kcal/min. at the intestine is needed. after gastric bypass gastric emptying is accelerated and less glucose is necessary to reach this threshold. the "threshold load" and "tolerable load without dumping symptoms" is not yet know.

Eligibility criteria:
inclusion criteria: * 6 weeks post gastric bypass surgery, * non-diabetic patient exclusion criteria: * smoker, * diabetes, * gastrointestinal motility disorder, * medication influencing gastric emptying

Keywords: glucose, blood
prospective evaluation of the incidence of nsf in patients with kidney disease undergoing mr

Conditions: Nephrogenic Systemic Fibrosis

Summary: phase 4, open-label, two-year, prospective, multi-center, follow-up study conducted at up 15 sites in usa. approximately 1,000 patients with moderate-to-severe ckd will be enrolled and followed for up to 24 months.

phase 4, open-label, two-year, prospective, multi-center, follow-up study will be conducted in up to 15 active sites in the united states. all patients will receive 1 dose of ablavar as part of an mri examination in their routine clinical management. prior to undergoing an ablavar mri, patients will have a baseline serum creatinine test within 24 hours prior to ablavar administration, will sign an informed consent (ic) form, will undergo a limited exam for skin abnormalities, and will undergo a brief medical history assessment on the day of and prior to ablavar administration. a standardized nsf questionnaire will be administered to the patient at 48 (+ or -12) hours, 1 month (+ or - 1 week), 3 months (+ or - 2 weeks), 6 (+ or - 1) months, and 18 (+ or - 1) months post-dose. at 12 (+ or - 1) months, and at 24 (+ or - 1) months. patients will return to the clinic for a limited examination for skin abnormalities and formal review of signs and symptoms suggestive of nsf.

Eligibility criteria:
inclusion criteria: kidney disease with gfr \< 60 ml/min./1.73 m\^2. clinical need to receive an mri with contrast. understand \& sign informed consent. exclusion criteria: history of known or suspected nsf. has received any gadolinium based contrast agent within 12 months prior to enrollment. has a clinically significant skin disorder which may interfere with detection of cutaneous nsf manifestations. has any medical condition or other circumstances which would significantly decrease the chances of obtaining reliable data and achieving study objectives. is unable or unwilling to return for necessary office visits or follow up calls, and/or to be examined by a physician or undergo deep skin biopsy should the development of nsf be suspected.

Keywords: nsf, ablavar, kidney disease, magnetic resonance imaging (mri),
the change of coagulation markers in children with β-thalassemia disease after stem cell transplantation

Conditions: Thalassemia

Summary: hypercoagulable state is well recognized in patients with β-thalassemia. evidences of hypercoagulability include abnormal expression of phosphatidylserine on red blood cell (rbc) surface and consequent increased platelet activation and thrombin generation. in addition, a reduction of anticoagulants i.e. proteins c and s and antithrombin (at) was demonstrated. however, coagulable state in patients with β-thalassemia following stem cell transplantation (sct) has not been characterized.

hypercoagulable state is well recognized in patients with β-thalassemia. evidences of hypercoagulability include abnormal expression of phosphatidylserine on red blood cell (rbc) surface and consequent increased platelet activation and thrombin generation. in addition, a reduction of anticoagulants i.e. proteins c and s and antithrombin (at) was demonstrated. however, coagulable state in patients with β-thalassemia following stem cell transplantation (sct) has not been characterized.therefore, the objective is to compare coagulation markers and anticoagulants among β-thalassemics with and without sct and normal control (nc).the subjects will be classified into 3 groups; β-thalassemia post sct (thal-sct), β-thalassemia treated with regular transfusion (thal-rt) and nc. blood samples will be tested for annexin v (an index of abnormal expression of phosphatidylserine on rbc surface), markers of activation of coagulation system (thrombin antithrombin complex (tat), prothrombin fragment (f1+2), and d-dimer) and anticoagulants (proteins c and s and at).

Eligibility criteria:
inclusion criteria: group 1: beta thalassemia major or beta thalassemia / hb e who receive regular transfusion therapy (thal- rt). the baseline hct was more than 24% for at least 6 months. group 2: beta thalassemia major or beta thalassemia / hb e post sct (thal-sct) who were discontinued immunosuppressive drugs. group 3: normal children (nc) who had normal hb/hct and mcv for age exclusion criteria: children with beta thalassemia major or beta thalassemia / hb e who have co-diseases such as immune hemolytic anemia, infection, or inflammatory diseases

Keywords: coagulation markers, thalassemia disease post sct
one-step universal adhesives: a 3-year clinical trial in class ii composite restorations

Conditions: Dental Caries Class II; Marginal Integrity of Composite Restorations With Universal Adhesives

Summary: to evaluate and compare the clinical performance and periodontal responses of four commercially available one-step universal adhesives with different formulations in class ii composite restorations over a three-year period.

the experimental design description adhered to the guidelines provided by the consolidated standards of reporting trials (consort) statement. the present study is planned as a double-blinded randomized clinical trial, ensuring that both the patients and the examiner are unaware of the treatment allocation. the trial will follow a split-mouth design. a total of forty-eight adult patients, who are seeking dental treatment, will be enrolled in the study. the participants will be recruited from the outpatient clinic at faculty of dentistry, mansoura university. no active advertisement will be used for participant recruitment, and instead, a convenience sample will be formed. prior to participating in the study, each patient will be required to provide informed consent by signing a consent form. the protocol of the study was approved by mansoura university's ethics committee before initiation

Eligibility criteria:
inclusion criteria: * patients must present with at least four posterior primary compound proximal caries involving two surfaces, specifically occluso-mesial or occluso-distal cavities, with a corresponding international caries detection and assessment system (icdas) score of 4 or 5. * the buccolingual width of the lesion should be approximately less than two-thirds of the intercuspal distance. * teeth to be restored must be in normal occlusion with the natural antagonist teeth. * vital teeth with no signs of pulpal inflammation or pathological lesions. * normal periodontal status and good oral hygiene. * good likelihood of recall availability. exclusion criteria: * patients with proximal cavities that extend beyond two surfaces or have a lesion buccolingual width greater than two-thirds of the intercuspal distance, or requiring cusp coverage. * partly erupted or endodontic treated teeth. * poor oral hygiene or severe periodontitis. * absence of neighboring or antagonist teeth. * patients with known allergy to any component of the study materials. * patients with unstable medical conditions. * patients with known unavailability to attend recall visits. * pregnant or lactating females. * patients with heavy para-functional habits, fractured, or visibly cracked teeth.
institut paoli calmettes acute leukemia database

Conditions: Acute Leukemia Diagnosis

Summary: database of institut paoli-calmettes patients diagnosed with acute leukemia


Eligibility criteria:
inclusion criteria: * patient with a diagnosis of acute leukemia exclusion criteria: * non applicable